TY - JOUR
T1 - ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants
AU - van Doremalen, Neeltje
AU - Schulz, Jonathan E.
AU - Adney, Danielle R.
AU - Saturday, Taylor A.
AU - Fischer, Robert J.
AU - Yinda, Claude Kwe
AU - Thakur, Nazia
AU - Newman, Joseph
AU - Ulaszewska, Marta
AU - Belij-Rammerstorfer, Sandra
AU - Saturday, Greg
AU - Spencer, Alexandra J.
AU - Bailey, Dalan
AU - Russell, Colin A.
AU - Gilbert, Sarah C.
AU - Lambe, Teresa
AU - Munster, Vincent J.
N1 - Funding Information: We would like to thank Mehul Suthar, Kathleen Cordova, Brian Smith, Jade Riopelle, Julia Port, Shane Gallogly, Julie Callison, Lara Myers, Nicolette Arndt, Trenton Bushmaker, Linda Couey, Brian Mosbrucker, Amanda Weidow, Natalie Thornburg, Sue Tong, Ranjan Mukul, Brandi Williamson, Myndi Holbrook, Emmie de Wit, Kyle Rosenke, Meaghan Flagg, Matthew Lewis, Craig Martens, Kent Barbian, Stacey Ricklefs, Sarah Anzick, Andrew Pekosz, Bin Zhou, Sujatha Rashid, Kimberly Stemple, Alan Sutherland, Anita Mora, and the animal care takers for their assistance during the study. Isolate hCoV-19/USA/MD-HP01542/2021 was obtained from Andrew Pekosz, John Hopkins Bloomberg School of Public Health. Isolate hCoV-19/USA/GA-EHC-2811C/2021 was obtained from Mehul Suthar, University Emory School of Medicine. The following reagent was deposited by the Centers for Disease Control and Prevention and obtained through BEI Resources, NIAID, NIH: hCoV-19/USA/KY-CDC-2-4242084/2021. This work was supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) (1ZIAAI001179-01, VJM), and AstraZeneca (SCG). The funders were not involved in study design, data collection or analysis. Funding Information: We would like to thank Mehul Suthar, Kathleen Cordova, Brian Smith, Jade Riopelle, Julia Port, Shane Gallogly, Julie Callison, Lara Myers, Nicolette Arndt, Trenton Bushmaker, Linda Couey, Brian Mosbrucker, Amanda Weidow, Natalie Thornburg, Sue Tong, Ranjan Mukul, Brandi Williamson, Myndi Holbrook, Emmie de Wit, Kyle Rosenke, Meaghan Flagg, Matthew Lewis, Craig Martens, Kent Barbian, Stacey Ricklefs, Sarah Anzick, Andrew Pekosz, Bin Zhou, Sujatha Rashid, Kimberly Stemple, Alan Sutherland, Anita Mora, and the animal care takers for their assistance during the study. Isolate hCoV-19/USA/MD-HP01542/2021 was obtained from Andrew Pekosz, John Hopkins Bloomberg School of Public Health. Isolate hCoV-19/USA/GA-EHC-2811C/2021 was obtained from Mehul Suthar, University Emory School of Medicine. The following reagent was deposited by the Centers for Disease Control and Prevention and obtained through BEI Resources, NIAID, NIH: hCoV-19/USA/KY-CDC-2-4242084/2021. This work was supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) (1ZIAAI001179-01, VJM), and AstraZeneca (SCG). The funders were not involved in study design, data collection or analysis. Publisher Copyright: © 2022, This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
PY - 2022/12/1
Y1 - 2022/12/1
N2 - ChAdOx1 nCoV-19 (AZD1222) is a replication-deficient simian adenovirus–vectored vaccine encoding the spike (S) protein of SARS-CoV-2, based on the first published full-length sequence (Wuhan-1). AZD1222 has been shown to have 74% vaccine efficacy against symptomatic disease in clinical trials. However, variants of concern (VoCs) have been detected, with substitutions that are associated with a reduction in virus neutralizing antibody titer. Updating vaccines to include S proteins of VoCs may be beneficial, even though current real-world data is suggesting good efficacy following boosting with vaccines encoding the ancestral S protein. Using the Syrian hamster model, we evaluate the effect of a single dose of AZD2816, encoding the S protein of the Beta VoC, and efficacy of AZD1222/AZD2816 as a heterologous primary series against challenge with the Beta or Delta variant. Minimal to no viral sgRNA could be detected in lungs of vaccinated animals obtained at 3- or 5- days post inoculation, in contrast to lungs of control animals. In Omicron-challenged hamsters, a single dose of AZD2816 or AZD1222 reduced virus shedding. Thus, these vaccination regimens are protective against the Beta, Delta, and Omicron VoCs in the hamster model.
AB - ChAdOx1 nCoV-19 (AZD1222) is a replication-deficient simian adenovirus–vectored vaccine encoding the spike (S) protein of SARS-CoV-2, based on the first published full-length sequence (Wuhan-1). AZD1222 has been shown to have 74% vaccine efficacy against symptomatic disease in clinical trials. However, variants of concern (VoCs) have been detected, with substitutions that are associated with a reduction in virus neutralizing antibody titer. Updating vaccines to include S proteins of VoCs may be beneficial, even though current real-world data is suggesting good efficacy following boosting with vaccines encoding the ancestral S protein. Using the Syrian hamster model, we evaluate the effect of a single dose of AZD2816, encoding the S protein of the Beta VoC, and efficacy of AZD1222/AZD2816 as a heterologous primary series against challenge with the Beta or Delta variant. Minimal to no viral sgRNA could be detected in lungs of vaccinated animals obtained at 3- or 5- days post inoculation, in contrast to lungs of control animals. In Omicron-challenged hamsters, a single dose of AZD2816 or AZD1222 reduced virus shedding. Thus, these vaccination regimens are protective against the Beta, Delta, and Omicron VoCs in the hamster model.
UR - http://www.scopus.com/inward/record.url?scp=85135552395&partnerID=8YFLogxK
U2 - https://doi.org/10.1038/s41467-022-32248-6
DO - https://doi.org/10.1038/s41467-022-32248-6
M3 - Article
C2 - 35941149
SN - 2041-1723
VL - 13
JO - Nature communications
JF - Nature communications
IS - 1
M1 - 4610
ER -